Peptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer
- 28 May 2013
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 4 (1) , 1923
Abstract
The growth of advanced prostate cancer depends on androgen receptor signalling, however treatment options are limited. Here we report the disruption of specific protein–protein interactions involving LXXLL motifs in androgen receptor–coregulator proteins such as PELP1 using a novel, small molecule peptidomimetic (D2). D2 is stable, non-toxic and efficiently taken up by prostate cancer cells. Importantly, D2 blocks androgen-induced nuclear uptake and genomic activity of the androgen receptor. Furthermore, D2 abrogates androgen-induced proliferation of prostate cancer cells in vitro with an IC50 of 40 nM, and inhibits tumour growth in a mouse xenograft model. D2 also disrupts androgen receptor–coregulator interactions in ex vivo cultures of primary human prostate tumours. These findings provide evidence that targeting androgen receptor–coregulator interactions using peptidomimetics may be a viable therapeutic approach for patients with advanced prostate cancer.Keywords
This publication has 43 references indexed in Scilit:
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- PELP1: A novel therapeutic target for hormonal cancersIUBMB Life, 2010
- Coactivator selective regulation of androgen receptor activitySteroids, 2009
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate CancerCell, 2009
- Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interactionChemical Communications, 2009
- Unraveling the Complexities of Androgen Receptor Signaling in Prostate Cancer CellsCancer Cell, 2009
- Design, Synthesis, and Evaluation of an α-Helix Mimetic Library Targeting Protein−Protein InteractionsJournal of the American Chemical Society, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Mechanisms mediating androgen receptor reactivation after castrationUrologic Oncology: Seminars and Original Investigations, 2009
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003